Compare iShares International Treasury Bond ETF (IGOV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Moderna, Inc. — how do they compare? iShares International Treasury Bond ETF trades at $40.63, while Moderna, Inc. trades at $59.32 (market cap $23.60B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | MRNA | |
|---|---|---|
52-Week High | $43.09 | $81.80 |
52-Week Low | $40.54 | $22.36 |
Market Cap | — | $23.60B |
Sector | — | Health |
Enterprise Value | — | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, trading at $40.68, is experiencing a slight decline of 0.22% today amid a bearish technical signal, with moving averages indicating strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins, while recent news highlights significant downside risks from global inflationary pressures affecting its bond holdings.
The outlook for IGOV is cautious due to high duration exposure amplifying capital losses in a rising rate environment. Investment opportunities are limited without clear financial metrics, and risks include persistent energy issues and geopolitical tensions that could further impact performance.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
